Inductos (Dibotermin Alfa)

Dibotermin alfa activates bone morphogenetic protein receptors on mesenchymal cells, triggering SMAD‑mediated signaling pathways. This cascade promotes the differentiation of progenitor cells into osteoblasts and stimulates the synthesis of bone matrix, leading to accelerated new bone formation at the implantation site.

The specific dose and implant size of Inductos are determined by the operating surgeon based on the patient’s anatomy, the surgical indication, and the desired bone‑growth outcome. Prescribers select the appropriate amount according to clinical guidelines and individual case requirements.

Safety data for dibotermin alfa in pregnant or lactating individuals are limited. The product should only be used during pregnancy or breastfeeding if the potential benefits justify the potential risks, and the decision must be made by the treating physician.

To request Inductos, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Inductos delivers dibotermin alfa in a sterile implant format, offering controlled local release at the surgical site. Compared with other BMP products that may be supplied as powders or gels, the implant provides precise placement, reduced handling steps, and consistent dosing, which can simplify the operative workflow.

Inductos must be stored at 2‑8 °C in a refrigerator. Keep the implant in its original packaging, protect it from light, and avoid freezing or shaking. If temperature excursions occur, follow the manufacturer’s stability guidelines before use.

Inductos is implanted directly into the surgical site during the operative procedure. The surgeon positions the sterile implant within the bone defect or fusion area, ensuring stable fixation before closing the wound. No additional systemic administration is required.

Serious risks associated with Inductos include severe infection at the implant site, allergic or hypersensitivity reactions, ectopic bone formation that may compress adjacent structures, and rare cases of malignant transformation. Prompt recognition and management of these events are essential.

Inductos is contraindicated in patients with known hypersensitivity to dibotermin alfa or any component of the implant, active infection at the intended implantation site, or a diagnosed malignancy in the area where the implant would be placed. Clinical judgment should guide use in other special populations.